Camacho-HaliliMGeorgeRGottesmanMDavis-LortonM. An approach to natalizumab hypersensitivity: a case series of induction of tolerance. Mult Scler2011; 17: 250–253.
2.
PolmanCHO’ConnorPWHavrdovaE. for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
3.
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Published 28May2009 (v4.03: 14 June 2010). Available at: http://ctep.cancer.gov/forms/CTCAEv4.pdf.
4.
BrockowKRomanoABlancaMRingJPichlerWDemolyP. General consideration for skin test procedures in the diagnosis of drug hypersensitivity. Allergy2002; 57: 45–51.
5.
BrennanPJRodriguez BouzaTHsuFISloaneDECastellsMC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients from evaluation to treatment. J Allergy Clin Immunol2009; 124: 1259–1266.
6.
Munoz-CanoRCarnésJSanchez-LopezJ. Biological agents: new drugs, old problems. J Allergy Clin Immunol2010; 126: 394–395.
7.
OttHStanzelSOcklenburgCMerkHFBaronJMLehmannS. Total serum IgE as a parameter to differentiate between intrinsic and extrinsic atopic dermatitis in children. Acta Derm Venereol2009; 89: 257–261.
8.
ChristensenLHHolmJLundGRiiseELundK. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol2008; 122: 298–304.
